Zhejiang Cheng Yi Pharmaceutical (603811.SH): A total of 2.13% of shares have been repurchased.

On December 23, Gelonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that as of December 23, 2024, the company has repurchased a total of 6,960,220 shares through centralized bidding trading, accounting for 2.13% of the company's total share capital, an increase of 0.52% compared to the last disclosed figure, with a highest Fill Price of 8.36 yuan/share and a lowest Fill Price of 7.36 yuan/share, and a total amount of funds paid of 55,988,366 yuan (excluding transaction fees).

Gelonghui FinanceDec 23 03:34 ET

Zhejiang Cheng Yi Pharmaceutical (603811.SH): Fish oil health foods and pharmaceutical glucosamine both fall under the category of the silver economy.

On December 20, Glonghui reported that Zhejiang Cheng Yi Pharmaceutical (603811.SH) stated on the investor interaction platform that our fish oil health food and pharmaceutical glucosamine fall under the category of the silver economy. The company has opened an 'Official Flagship Store' on JD.com to sell fish oil and other health foods like phosphatidylserine, and it is also possible to search for 'Cheng Yi Big Health' on the Wechat Mini Program to purchase Cheng Yi fish oil softgel health food. Additionally, quality Dealers are welcomed to collaborate and join. Furthermore, the company is currently negotiating cooperation matters with some domestic e-commerce companies.

Gelonghui FinanceDec 20 02:49 ET

Cheng Yi Pharma Gets Nod to Amendments in Amikacin Sulfate Injection

MT NewswiresDec 18 05:51 ET

Zhejiang Cheng Yi Pharmaceutical (603811.SH): Amikacin sulfate injection has passed the consistency evaluation of generic drugs.

Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that it recently received approval issued by the National Medical Products Administration...

Zhitong FinanceDec 17 02:33 ET

Zhejiang Cheng Yi Pharmaceutical (603811.SH): The marine biomedical manufacturing project has been completed in this period

Gelonghui 18th November | Zhejiang Cheng Yi Pharmaceutical (603811.SH) stated at the performance briefing that the marine biomedical manufacturing project has been completed in this period. The company is advancing the construction of the "Two Strong and One Major Project", including high-purity fish oil, in accordance with the requirements of being the largest in Asia, with the lowest cost and the best quality. With the gradual expansion of the market, the future of the high-purity fish oil market looks promising.

Gelonghui FinanceNov 18 03:44 ET

Why Zhejiang Cheng Yi Pharmaceutical's (SHSE:603811) Shaky Earnings Are Just The Beginning Of Its Problems

Simply Wall StNov 7 17:23 ET